Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ ASX Shares
3 quality blue chip ASX shares to buy in November
Share Market News
ResMed shares higher after earnings beat
Share Market News
Top brokers name 3 ASX shares to sell today
Share Market News
5 things to watch on the ASX 200 on Wednesday
Share Market News
ALL ORDINARIES finishes higher Tuesday: 8 ASX shares you missed
Share Fallers
Why Cann, Cochlear, Megaport, & Super Retail shares tumbled lower today
Share Market News
ASX 200 lunch update: NAB higher, Cochlear and Super Retail lower
Share Market News
Has Cochlear got its "head in the sand" over potential $380 million legal bill?
Share Fallers
Cochlear share price drops lower on AGM update
Share Market News
Is Medical Developments International the next ResMed?
⏸️ ASX Shares
These ASX healthcare shares could be long-term market beaters
Share Market News
Why the Fisher & Paykel Healthcare share price just hit a 52-week high
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
